Neurology® Podcast

Dr. Stacey Clardy focuses her discussion with Dr. Amanda Grennell on an update on Zika for 2019. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z.

In the first segment, Dr. Stacey Clardy talks with Dr. Anastasia Zekeridou about her paper on Phosphodiesterase 10A-IgG, a novel biomarker of paraneoplastic neurological autoimmunity. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Prof. Robin Feldman on "evergreening" and drug prices. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Jason Crowell talks with Dr. Michele Hu and Dr. David Okai about their longitudinal study of the severity of impulse control disorders in Parkinson disease and RBD. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Heidi Ledford on her Nature article discussing CRISPR babies and what would be required to make gene editing safe and acceptable. Read the full article here: https://www.nature.com/articles/d41586-019-01906-z. Disclosures can be found at Neurology.org. CME Opportunity: Listen to this week's Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

In the first segment, Dr. Stacey Clardy talks with Dr. Robert Zivadinov about cumulative gadodiamide administration leading to brain gadolinium deposition in early MS. In the second part of the podcast, Dr. Jeffrey Ratliff focuses his discussion with Dr. Michael D. Fox on his Brain paper on network localization of cervical dystonia based on causal brain lesions. You can read the paper here: https://academic.oup.com/brain/article-abstract/142/6/1660/5491101?redirectedFrom=fulltext.

This month's Delayed Recall highlights more interviews from our new podcast offering, Neurology Minute. In 2019, Neurology launched a new podcast perfect for Alexa and other similar devices. This episode features digestible "minutes" from June and July. See the instructions for enabling the Neurology Minute on Amazon Alexa below:

In the first segment, Dr. Kristen Heinan talks with Dr. Barbara Weissman about her Neurology: Clinical Practice paper on recommendations for neurologists on the CDC's Guideline on Pediatric Mild Traumatic Brain Injury. In the second part of the podcast, Dr. Will Rondeau focuses his discussion with Dr. Geoffrey Donnan on his NEJM paper on thrombolysis guided by perfusion Imaging up to 9 hours after onset of stroke. You can read the paper here: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1813046.

In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. Sarah Tabrizi talks about targeting Huntington expression in patients with Huntington's disease in her interview with Dr. Jeffrey Ratliff. Read Dr. Tabrizi's paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article.

In the first segment, Dr. Halley Alexander talks with Dr. Orrin Devinsky about his paper on the full spectrum of epilepsies and the North American SUDEP Registry. In the second part of the podcast, Dr. Ted Burns focuses his discussion with Dr. Gil Wolfe on his Lancet Neurology paper on the long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis. You can read the paper here: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30392-2/fulltext.

In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration's authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.

In the first segment, Dr. Michelle Mauermann talks with Dr. Bart Jacobs about his paper on current treatment practice of Guillain-Barré syndrome. In the second part of the podcast, Dr. Matthew Harms focuses his discussion with Dr. Guy Rouleau on his Neurology: Genetics paper looking at how somatic expansion of the C9orf72 Hexanucleotide Repeat does not occur in ALS spinal cord tissues.